Advertisement
Advertisement
U.S. markets open in 7 hours 33 minutes
Advertisement
Advertisement
Advertisement
Advertisement

CIT: SPA Balanced Portfolio Class R6 (WSPABX)

Nasdaq - Nasdaq Delayed Price. Currency in USD
13.63-0.09 (-0.66%)
At close: 08:01PM EST
Advertisement
Full screen
Loading interactive chart...
  • PR Newswire

    NICE recommends Revestive® ▼ (teduglutide) for the treatment of adults and children living with Short Bowel Syndrome (SBS)

    Takeda UK Ltd. today announced that the National Institute for Health and Care Excellence (NICE), the health technology appraisal body in England and Wales, has published its Final Appraisal Document (FAD) recommending Revestive® ▼ (teduglutide) once daily subcutaneous injection as an option for people living with Short Bowel Syndrome (SBS) aged 1 year and above.[ii] Individuals should be stable following a period of intestinal adaptation after surgery.[vii]

  • Business Wire

    Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA

    CAMBRIDGE, Mass. & OSAKA, Japan, May 31, 2022--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it will present data at two upcoming scientific congresses this spring: the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7 in Chicago, Ill. and the 30th Congress of the European Hematology Association (EHA), June 9-12 in Vienna, Austria. Takeda’s latest research in oncology focuses on enhancing and improving patient care while

  • Business Wire

    Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna

    CAMBRIDGE, Mass. & OSAKA, Japan, May 31, 2022--Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda (TSE:4502/NYSE:TAK) announced to transfer the marketing authorization in Japan for Moderna’s COVID-19 vaccine Spikevax™ (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022.

Advertisement
Advertisement